This approach holds promise in potentially attenuating NF‐κB activity, modulating cytokine storms, and mitigating the onset of ARDS in individuals diagnosed with COVID‐19 pneumonia.52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63. This evidence concerns the gene NFKB1 and acute respiratory distress syndrome.